DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Inflammation; Barrett's Esophagus

Intervention: dexlansoprazole (Drug); Omeprazole (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Mayo Clinic

Official(s) and/or principal investigator(s):
Ganapathy Prasad, MD, Principal Investigator, Affiliation: Mayo Clinic

Summary

The investigators hypothesize that intensive acid suppression with a long acting high potency proton pump inhibitor (dexlansoprazole) will lead to a greater decrease in levels of inflammatory mediators (compared to conventional PPIs) in the esophagus, which could potentially lead to decreased recurrence of intestinal metaplasia following endoscopic ablation.

Clinical Details

Official title: Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Inflammation reduction

Eligibility

Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Patients who have undergone ablation for BE and HGD or LGD with PDT/Radiofrequency ablation and endoscopic mucosal resection who have no endoscopic and histologic evidence of specialized intestinal metaplasia on biopsies from the esophagus on two successive endoscopies post ablation will be offered enrollment in the study. Inclusion criteria: 1. Absence of intestinal metaplasia on endoscopy (under Narrow Band Imaging) and on histology (from biopsies taken from gastroesophageal junction and distal esophagus) on two successive surveillance endoscopies. 2. Able to consent to study 3. Males and females age 18-90 4. Life expectancy of 5 years or greater. Exclusion criteria: 1. Pregnancy 2. Inability to consent for the procedure 3. Anticoagulation therapy precluding performance of ambulatory pH monitoring and/or biopsies 4. Intolerance to proton pump inhibitors 5. Elevation in AST, ALT, Bilirubin or alkaline phosphatase more than five times the upper limit of normal.

Locations and Contacts

Mayo Clinic in Rochester, Rochester, Minnesota 55905, United States
Additional Information

Starting date: March 2010
Last updated: December 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017